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We describe the first known case of a device-related
bloodstream infection caused by Staphylococcus aureus
small colony variants. Recurrent pacemaker-related blood-
stream infection within a 7-month period illustrates the poor
clinical and microbiologic response to prolonged antimicro-
bial therapy in a patient infected with this S. aureus sub-
population.
I
nfections caused by Staphylococcus aureus range from
mild skin infections to acute life-threatening diseases
such as pneumonia, osteomyelitis, and endocarditis.
However, S. aureus may also cause a chronic disease with
persistent and recurrent infections. Skin and soft tissue
infections, chronic osteomyelitis, and persistent infections
in patients with cystic fibrosis have been associated with
small colony variants, a naturally occurring subpopulation
of the species S. aureus (1–6). S. aureus small colony vari-
ants are characterized as electron transport deficient bacte-
ria because of their auxotrophism to hemin or menadione
or are recognized as thymidine-dependent. These variants
produce very small, mostly nonpigmented and non-
hemolytic colonies. In addition, they also demonstrate var-
ious other features that are atypical for S. aureus, including
reduced coagulase production, failure to use mannitol, and
increased resistance to aminoglycosides and cell-wall
active antibiotics (3–10). Furthermore, the ability of these
variants to persist intracellularly within nonprofessional
phagocytes has been described (3,5,11). Because of their
fastidious growth characteristics and unusual morphologic
appearance, small colony variants present a challenge both
to the microbiologist and the clinician, often resulting in
misidentification and misinterpretation (1,2,7,8).
Prerequisite for recovering and identifying these variants
is the application of extended conventional culture and
identification techniques (3,5,8). We report the first case of
a pacemaker-related bloodstream infection caused by S.
aureus small colony variants. This case illustrates the poor
clinical and microbiologic response to prolonged antimi-
crobial therapy in patients infected with these variants.
Case Report
A 63-year-old man was transferred to our facility with
the presumptive diagnosis of endocarditis related to a
pacemaker-lead infection. Past medical history included
hypertension, coronary artery disease, and noninsulin-
dependent diabetes mellitus. A VVI (ventricular ventricu-
lar inhibited) pacemaker had been implanted for treatment
of sick sinus syndrome 9 years earlier. Six weeks before
admission, this device had been removed because of a
pocket infection after blunt trauma with dislocation of the
device and perforation of the skin. Specimens for microbi-
ologic culture were not obtained at this time. The pace-
maker leads were left in place, a gentamicin-containing
sponge was applied to the infection site, and a new pace-
maker was implanted on the other side of the chest. Four
weeks later, the patient sought treatment at the local hospi-
tal for a high fever (39.7°C) and chills and a subcutaneous
abscess with oxacillin-susceptible S. aureus at the primary
insertion site. After surgical drainage, antimicrobial thera-
py was initiated with intravenous cefuroxime. The remain-
ing pacemaker leads were partially cut but not completely
removed. Ten days later, spiking fever and chills unrespon-
sive to the administration of meropenem and vancomycin
developed, and the patient was transferred to our medical
center for pacemaker ablation. The physical examination
did not indicate auscultation abnormalities or stigmata of
endocarditis. Laboratory studies were unremarkable
except a C-reactive protein (CRP) level of 170 mg/L (nor-
mal value <8 mg/L) and a blood sedimentation rate of 79
mm/h. Multiple blood cultures taken on admission
remained negative. Transesophageal echocardiography did
not show vegetations or other evidence of endocarditis. On
hospital day 6, the new pacemaker was completely
removed by percutaneous ablation as were the remaining
leads of the old device. Only the tip of the pacemaker lead
remained fixed in the myocardium,  and surgical removal
involving extracorporal circulation was not attempted. The
patient’s condition improved rapidly, CRPlevel returned to
normal, and on hospital day 32, the patient was transferred
to the local hospital to complete a 6-week course of intra-
venous vancomycin and rifampin as empirical antistaphy-
lococcal therapy. Before transfer, the daily vancomycin
dose had been reduced to 250 mg twice a day after an ele-
vated vancomycin serum level. Eight days later, the patient
was readmitted with recurrent high fever. Blood cultures
taken on readmission were again negative. After the van-
comycin dose was increased to 500 mg every 12 hours, the
patient promptly became afebrile. Antimicrobial therapy
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week course of vancomycin and rifampin. Three days later,
the patient again had spiking fever. After 6 to 48 hours of
incubation, four sets of blood cultures obtained on four
consecutive days yielded nonpigmented and nonhemolytic
staphylococci, initially identified on the basis of a negative
tube coagulation test and the API ID 32 Staph system
(bioMérieux, Marcy-L’Etoile, France) as coagulase-nega-
tive staphylococci, susceptible to oxacillin (MIC 0.5
mg/mL) and vancomycin (MIC 1.0 mg/mL) but resistant
to rifampin (MIC >32 mg/mL). However, the colony mor-
phologic findings were suggestive of small colony variants
of  S. aureus, confirmed by polymerase chain reaction
amplification of the nuc and coa genes as well as by deter-
mination of the strain’s auxotrophy for hemin. The patient
responded promptly to flucloxacillin, 4 g intravenously
three times a day. After another 6-week course of parenter-
al therapy, antimicrobial therapy was discontinued, and the
patient was discharged (CRP 7 mg/L, ESR 35 mm/h); he
was readmitted after 6 days with chills and high fever.
Antimicrobial therapy with intravenous flucloxacillin was
resumed and followed by immediate defervescence. Three
blood cultures taken on readmission were again positive
with S. aureus small colony variants. Clonal identity of all
isolates was demonstrated by pulsed-field gel elec-
trophoresis of bacterial DNA (data not shown). A trans-
esophageal echocardiogram showed the residual tip of the
pacemaker lead fixed in the myocardial septum without
vegetations. The remaining device was finally removed by
open-heart surgery with use of cardiopulmonary bypass.
Microbiologic culture of the pacemaker electrode per-
formed at a different institution yielded abundant growth
of staphylococci that were misidentified as S. warneri,
showing the same biochemical profile as the previously
isolated bacteria as determined by the ID 32 Staph system.
The patient recovered completely and was discharged on
the 10th postoperative day after a total hospital course of 7
months. 
Conclusions
S. aureus small colony variants have been implicated in
persistent and recurrent infections that give a poor clinical
and bacteriologic response to standard antimicrobial thera-
py in patients with abscess, chronic osteomyelitis, and
bronchopulmonary infections, particularly after prolonged
exposure to antibiotics (1–6). Bloodstream infection relat-
ed to an implantable intravascular device with this S.
aureus variant has not been reported before. These pheno-
typic variants are characterized by their fastidious growth
and atypical colony morphologic findings on routine
media, making recovery as well as correct identification
difficult for microbiologic laboratories (3,5,8). The ability
to interrupt electron transport and to form a variant sub-
population affords S. aureus a number of survival advan-
tages, including the ability of this subpopulation to persist
intracellularly within nonprofessional phagocytes (11,12).
The intracellular position may shield small colony variants
from host defenses and decrease exposure to antibiotics
(3,5,11). S. aureus small colony variants can be selected by
gentamicin in vitro and in vivo as shown in patients with
osteomyelitis after gentamicin bead placement (4,12).
Chuard et al. demonstrated that, in contrast to their normal
phenotype parental strain, S. aureus small colony variants
that were attached to fibronectin-coated coverslips were
highly resistant to cell-wall–active antimicrobial agents
such as oxacillin and vancomycin (13). 
In our case, findings suggest that S. aureus small
colony variants might have been selected from the parent
strain population with a normal phenotype after exposure
to the locally applied aminoglycoside or to the prolonged
administration of vancomycin. Continually positive blood
cultures with the same strain as demonstrated by molecu-
lar typing and the presumable persistence of these organ-
isms on the pacemaker lead tip may partly be explained by
the poor effectiveness of vancomycin and flucloxacillin
against these slow-growing organisms that were adhering
to the remaining foreign body and the ability of these vari-
ants to persist intracellularly (7,8,13).
This case adds to the spectrum of persistent and relaps-
ing infections attributed to S. aureus small colony variants
and emphasizes that these variants may also play a role in
intravascular device–related infections. It also illustrates
that complete removal of any foreign body material is
essential for the complete cure of prosthetic intravascular
device–related S. aureus infection. Laboratories should be
particularly alert for S. aureus small colony variants when
samples are submitted from patients who have received
long-term antimicrobial therapy, especially if the infection
is unusually persistent or recurrent.
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